Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

Supernus Pharmaceuticals is reaping the benefits of its ADHD drug Qelbree, with strong Q3 results and upwardly revised ...

For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

While Parkinson’s disease (PD) has a large and highly generalised ... to their efficacy against core PD motor symptoms. The PD drug development pipeline across the seven major markets (7MM ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Voyager Therapeutics Inc. ( (VYGR) ) has released its Q3 earnings. Here is a breakdown of the information Voyager Therapeutics Inc. presented ...

BMS-986446 (formerly PRX005) is designed to be a best-in-class anti-tau, MTBR-specific antibody for the potential ... for the treatment of Parkinson’s disease (PD). A phase II study, PASADENA, is ...

One asset, tapavadon, for treatment of Parkinson’s disease has already succeeded with a positive phase 3 readout in September ...